About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
PMID: 32880997 Journal: ALLERGY Year: 2021 Reference: Allergy. 2021 May;76(5):1493-1506. doi: 10.1111/all.14580. Epub 2020 Sep 29. Impact factor: 13.146 Publication type: Review in international publication Authors: Regent, Lynne, Sanchez, Angel, Vlieg-Boerstra, Berber, Roberts, Graham, Oude Elberink, Hanneke, Michaelis, Louise J, Jensen, Britt, de Silva, Debra, Singh, Chris, Muraro, Antonella et al. DOI: 10.1111/all.14580
PMID: 33289951 Journal: ALLERGY Year: 2021 Reference: Allergy. 2021 May;76(5):1480-1492. doi: 10.1111/all.14689. Epub 2020 Dec 22. Impact factor: 13.146 Publication type: Paper in international publication Authors: Sanchez-Lopez, Jaime, Araujo, Giovanna, Cardona, Victoria, Garcia-Moral, Alba, Casas-Saucedo, Rocio, Guilarte, Mar, Jose Torres, Maria, Dona, Inmaculada, Picado, Cesar, Pascal, Mariona et al. DOI: 10.1111/all.14689
PMID: 33983413 Journal: RHEUMATOLOGY Year: 2021 Reference: Rheumatology (Oxford). 2021 Nov 3;60(11):4956-4957. doi: 10.1093/rheumatology/keab433. Impact factor: 7.58 Publication type: Editorail in international publication Authors: Selva-O'Callaghan, Albert, Simeon-Aznar, Carmen Pilar et al. DOI: 10.1093/rheumatology/keab433
PMID: 33043475 Journal: ALLERGY Year: 2021 Reference: Allergy. 2021 May;76(5):1507-1516. doi: 10.1111/all.14626. Epub 2020 Nov 4. Impact factor: 13.146 Publication type: Paper in international publication Authors: Galvan-Blasco, Paula, Sala-Cunill, Anna, Luengo, Olga, Curran, Adrian, Moreno, Nuria, Labrador-Horrillo, Moises, Guilarte, Mar, Gonzalez-Medina, Monica, Victoria, Cardona et al. DOI: 10.1111/all.14626
PMID: 30738005 Journal: ALLERGY Year: 2019 Reference: Allergy. 2019 Jul;74(7):1384-1386. doi: 10.1111/all.13735. Epub 2019 Mar 14. Impact factor: 6.771 Publication type: Letter whit IF Authors: Gil-Serrano, Ingrid Johana, Galvan-Blasco, Paula, Guilarte, Mar, Cardona, Victoria, Labrador-Horrillo, Moises, Sala-Cunill, Anna, Luengo, Olga et al. DOI: 10.1111/all.13735
PMID: 30597424 Journal: JOURNAL OF PSYCHIATRIC RESEARCH Year: 2019 Reference: J Psychiatr Res. 2019 Mar;110:74-82. doi: 10.1016/j.jpsychires.2018.12.021. Epub 2018 Dec 24. Impact factor: 3.917 Publication type: Paper in international publication Authors: Gas, Cinta, Canales-Rodriguez, Erick Jorge, Radua, Joaquim, Abasolo, Nerea, Cortes, Maria Jose, Salvado, Ester, Muntane, Gerard, Aleman-Gomez, Yasser, Julia, Toni, Marsal, Sara et al. DOI: 10.1016/j.jpsychires.2018.12.021
PMID: 30704532 Journal: Health and Quality of Life Outcomes Year: 2019 Reference: Health Qual Life Outcomes. 2019 Jan 31;17(1):23. doi: 10.1186/s12955-019-1087-z. Impact factor: 2.318 Publication type: Paper in international publication Authors: Ferrer, Marta, Jauregui, Ignacio, Gimenez-Arnau, Ana, Bartra, Joan, Labrador-Horrillo, Moises, de Frutos, Javier Ortiz, Silvestre, Juan Francisco, Sastre, Joaquin, Velasco, Manuel, Valero, Antonio et al. DOI: 10.1186/s12955-019-1087-z
PMID: 30676319 Journal: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY Year: 2019 Reference: J Investig Allergol Clin Immunol. 2019;29(6):436-443. doi: 10.18176/jiaci.0373. Epub 2019 Jan 24. Impact factor: 3.802 Publication type: Paper in international publication Authors: Mateo-Borrega, M B, Garcia, B, Hernando Larramendi, C, Azofra, J, Gonzalez-Mancebo, E, Alvarado, M I, Nunez-Orjales, R, Dieguez, M C, Guilarte, M, Soriano-Galarraga, A M et al. DOI: 10.18176/jiaci.0373
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.
It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.
